Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
South Africa: New safety concerns emerge on latest HIV wonder drug

New safety concerns have emerged about the HIV drug dolutegravir, which the government plans to roll out in April.

Published
18 January 2019
From
Business Day
Back to the future with CD4 testing: Improving HIV care in low- and middle-income countries

A practical resource-based public health approach for the rapid initiation of antiretroviral therapy in HIV-infected individuals living in low- and middle-income countries could save thousands of lives, according to an Essay published January 15 in the open-access journal PLOS Medicine by Mark Tenforde of the University of Washington School of Medicine, and colleagues.

Published
16 January 2019
From
Science Daily
Dolutegravir monotherapy 'not a valid option' for patients with HIV

Study results showed that dolutegravir monotherapy “is not a valid option” to keep patients with chronic HIV infection virologically suppressed and should not be considered a treatment option, researchers said.

Published
15 January 2019
From
Healio
HIV protein function that slows migration of T cells also improves viral survival

A study from a Massachusetts General Hospital (MGH) research team has identified the specific function of a protein found in HIV and related viruses that appears to slow down viral spread in the earliest stages of infection. But they also found that, after initially slowing down the spread of infection, that function may help the virus survive later on by evading the immune response.

Published
15 January 2019
From
Medical Xpress
Larger HIV Reservoirs Found in Those with Clade B Subtype

A study team led by investigators from Simon Fraser University in Canada have made a key discovery on how viral factors, such as HIV subtypes, impact the size of the virus reservoirs in individuals with HIV.

Published
15 January 2019
From
Contagionlive.com
Sleep Abnormalities Do Not Reverse After Discontinuing Efavirenz

For patients with HIV receiving efavirenz-based therapy, sleep and neuropsychological abnormalities do not readily reverse after discontinuation of treatment, according to results published in HIV Clinical Trials.

Published
14 January 2019
From
Infectious Disease Advisor
Efavirenz Likely Safe for Pregnant HIV-Positive Women

The prevalence of birth defects following use of efavirenz (EVF)-based antiretroviral therapy (ART) is not statistically different from non-EFV-based ART during conception or in the first trimester, researchers say.

Published
09 January 2019
From
Medscape (requires free registration)
Dolutegravir Monotherapy for HIV No Longer Recommended

Dolutegravir monotherapy should no longer be used as HIV maintenance therapy, according to Bart J.A. Rijnders, MD, PhD, and Casper Rokx, MD, PhD, both from Erasmus Medical Center, Rotterdam, the Netherlands.

Published
09 January 2019
From
Contagion Live
‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

There are tens of thousands of immunologic non-responders in the U.S., whose low CD4 numbers put them at much higher risk of heart attacks, stroke, cancers, secondary infections such as tuberculosis, and death. And yet, drug companies and researchers aren’t actively pursuing new treatments that would boost their immunity.

Published
08 January 2019
From
STAT
The Road Ahead for HIV Cure Research

Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.

Published
08 January 2019
From
Poz
← First12345...200Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.